Interestingly, existing literature suggests that hypermethylation-mediated silencing of SLFN11 and SLFN12 disrupts DNA damage recognition, impairs apoptosis, and promotes chemoresistance across multiple cancers, allowing malignant cells to persist despite therapeutic intervention. Here, SLFN11 is linked to cancer.